High Technology Research Center, ‡Laboratory of Drug Design and Medicinal Chemistry and §Laboratory of Molecular and Cellular Pathophysiology, Showa Pharmaceutical University , 3-3165 Higashi-Tamagawagakuen, Machida, Tokyo 194-8543, Japan.
J Med Chem. 2013 Oct 10;56(19):7527-35. doi: 10.1021/jm400816v. Epub 2013 Sep 24.
Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) is a zinc-containing carboxypeptidase and significantly inhibits fibrinolysis. TAFIa inhibitors are thus expected to act as profibrinolytic agents. We recently reported the design and synthesis of selenium-containing inhibitors of TAFIa and their inhibitory activity. Here we report the crystal structures of potent selenium-, sulfur-, and phosphinic acid-containing inhibitors bound to porcine pancreatic carboxypeptidase B (ppCPB). ppCPB is a TAFIa homologue and is surrogate TAFIa for crystallographic analysis. Crystal structures of ppCPB complexed with selenium compound 1a, its sulfur analogue 2, and phosphinic acid derivative EF6265 were determined at 1.70, 2.15, and 1.90 Å resolution, respectively. Each inhibitor binds to the active site of ppCPB in a similar manner to that observed for previously reported inhibitors. Thus, in complexes, selenium, sulfur, and phosphinic acid oxygen coordinate to zinc in ppCPB. This is the first observation and report of selenium coordinating to zinc in CPB.
激活的凝血酶激活的纤溶抑制物(TAFIa)是一种含锌的羧肽酶,可显著抑制纤溶。因此,TAFIa 抑制剂有望作为纤维蛋白溶解增强剂。我们最近报道了 TAFIa 的含硒抑制剂的设计和合成及其抑制活性。在这里,我们报告了与猪胰羧肽酶 B(ppCPB)结合的强效硒、硫和膦酸抑制剂的晶体结构。ppCPB 是 TAFIa 的同源物,是用于晶体分析的替代 TAFIa。ppCPB 与硒化合物 1a、其硫类似物 2 和膦酸衍生物 EF6265 的复合物的晶体结构分别在 1.70、2.15 和 1.90 Å 分辨率下确定。每个抑制剂以与先前报道的抑制剂观察到的相似方式结合到 ppCPB 的活性部位。因此,在复合物中,硒、硫和膦酸氧与 ppCPB 中的锌配位。这是首次观察和报告 CPB 中的硒与锌配位。